EA201491213A1 - ANTAGONISTS TRPM8 - Google Patents
ANTAGONISTS TRPM8Info
- Publication number
- EA201491213A1 EA201491213A1 EA201491213A EA201491213A EA201491213A1 EA 201491213 A1 EA201491213 A1 EA 201491213A1 EA 201491213 A EA201491213 A EA 201491213A EA 201491213 A EA201491213 A EA 201491213A EA 201491213 A1 EA201491213 A1 EA 201491213A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- trpm8
- disorders
- antagonists
- compounds
- neurodegeneration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/40—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/42—One oxygen atom attached in position 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Изобретение относится к соединениям, действующим как селективные антагонисты члена 8 подсемейства М катионного канала транзиторного рецепторного потенциала (TRPM8) и имеющим формулу (I). Указанные соединения применимы при лечении заболеваний, связанных с активностью TRPM8, таких как боль, воспаление, ишемия, нейродегенерация, удар, психические расстройства, зуд, болезни раздраженного кишечника, вызванные холодом и обостренные респираторные расстройства и урологические расстройства.The invention relates to compounds acting as selective antagonists of member 8 of the subfamily M cation channel transient receptor potential (TRPM8) and having the formula (I). These compounds are useful in the treatment of diseases associated with TRPM8 activity, such as pain, inflammation, ischemia, neurodegeneration, stroke, mental disorders, itching, irritable bowel diseases caused by cold and exacerbated respiratory disorders and urological disorders.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11194365.0A EP2606888A1 (en) | 2011-12-19 | 2011-12-19 | Trpm8 antagonists |
EP12178327 | 2012-07-27 | ||
PCT/EP2012/076147 WO2013092711A1 (en) | 2011-12-19 | 2012-12-19 | Trpm8 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201491213A1 true EA201491213A1 (en) | 2014-11-28 |
EA025356B1 EA025356B1 (en) | 2016-12-30 |
Family
ID=47520061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491213A EA025356B1 (en) | 2011-12-19 | 2012-12-19 | Trpm8 antagonists |
Country Status (22)
Country | Link |
---|---|
US (2) | US9585875B2 (en) |
EP (1) | EP2793883B1 (en) |
JP (2) | JP6238906B2 (en) |
KR (1) | KR102000319B1 (en) |
CN (1) | CN104220069B (en) |
AU (1) | AU2012357747B2 (en) |
CY (1) | CY1120403T1 (en) |
DK (1) | DK2793883T3 (en) |
EA (1) | EA025356B1 (en) |
ES (1) | ES2676884T3 (en) |
HK (1) | HK1203810A1 (en) |
HR (1) | HRP20181086T1 (en) |
HU (1) | HUE038407T2 (en) |
LT (1) | LT2793883T (en) |
ME (1) | ME03038B (en) |
PL (1) | PL2793883T3 (en) |
PT (1) | PT2793883T (en) |
RS (1) | RS57389B1 (en) |
SI (1) | SI2793883T1 (en) |
TR (1) | TR201808861T4 (en) |
WO (1) | WO2013092711A1 (en) |
ZA (1) | ZA201404499B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2481727A1 (en) * | 2011-01-28 | 2012-08-01 | Dompe S.p.A. | TRPM8 receptor antagonists |
SI2793883T1 (en) | 2011-12-19 | 2018-08-31 | Dompe Farmaceutici S.P.A. | Trpm8 antagonists |
ES2721922T3 (en) | 2013-05-24 | 2019-08-06 | Nestle Sa | Treatment or prevention of non-inflammatory neuronal damage due to brain trauma and stroke using menthol, linalool and / or icilin |
WO2015185531A1 (en) | 2014-06-05 | 2015-12-10 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pesticides |
ES2724111T3 (en) | 2014-06-23 | 2019-09-06 | Dompe Farm Spa | 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8 inhibitors in the treatment of neuralgia, pain, COPD and asthma |
WO2017058594A1 (en) * | 2015-10-01 | 2017-04-06 | Senomyx, Inc. | Compounds useful as modulators of trpm8 |
EP3184524A1 (en) * | 2015-12-21 | 2017-06-28 | Dompé farmaceutici S.p.A. | 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists |
CA3022808A1 (en) | 2016-06-13 | 2017-12-21 | Mitsubishi Tanabe Pharma Corporation | Compositions for treating or preventing vasomotor symptoms |
WO2018117166A1 (en) * | 2016-12-21 | 2018-06-28 | キッセイ薬品工業株式会社 | Thiazole derivative or pharmacologically acceptable salt of same |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2713573A1 (en) * | 1977-03-28 | 1978-10-05 | Basf Ag | 4,5-DISUBSTITUTED THIAZOLES AND METHOD FOR MANUFACTURING THEM |
JPS59220687A (en) * | 1983-05-30 | 1984-12-12 | 株式会社日立製作所 | Method of controlling corrosion environment in reactor primary coolant circuit |
DK0513379T3 (en) * | 1990-11-30 | 1996-09-30 | Teijin Ltd | 2-Arylthiazole derivatives and pharmaceutical compositions containing them |
US6936629B2 (en) * | 2001-12-21 | 2005-08-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
CA2583015A1 (en) | 2004-10-13 | 2006-04-20 | Bayer Healthcare Ag | Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonists for the treatment of urological disorder |
WO2007017092A1 (en) | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Substituted 4-benzyloxy-benzoic acid amide derivatives |
WO2007017094A1 (en) | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Substituted benzyloxy-phenylmethylcarbamate derivatives |
WO2007017093A1 (en) | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Substituted 2-benzyloxy-benzoic acid amide derivatives |
WO2007080109A1 (en) | 2006-01-16 | 2007-07-19 | Bayer Healthcare Ag | Substituded benzyloxy-phenylmethylurea derivatives |
WO2007089031A1 (en) | 2006-02-01 | 2007-08-09 | Takeda Pharmaceutical Company Limited | Piperidine derivatives as tachykinin receptor antagonists |
CA2651865C (en) | 2006-05-10 | 2015-11-24 | Janssen Pharmaceutica N.V. | Cold menthol receptor-1 antagonists |
NZ582555A (en) | 2007-07-18 | 2012-06-29 | Janssen Pharmaceutica Nv | Sulfonamides as trpm8 modulators |
US8148422B2 (en) * | 2008-12-18 | 2012-04-03 | Janssen Pharmaceutica, Nv | Sulfonamides as TRPM8 modulators |
WO2010103381A1 (en) | 2009-03-13 | 2010-09-16 | Glenmark Pharmaceuticals S.A. | Spirocyclic piperidine derivatives as trpm 8 modulators |
KR20140071518A (en) | 2009-05-01 | 2014-06-12 | 라퀄리아 파마 인코포레이티드 | Sulfamoyl benzoic acid derivatives as trpm8 antagonists |
WO2012036233A1 (en) * | 2010-09-17 | 2012-03-22 | 塩野義製薬株式会社 | Condensed heterocyclic derivative having melanine-concentrating hormone receptor antagonistic activity |
SI2793883T1 (en) | 2011-12-19 | 2018-08-31 | Dompe Farmaceutici S.P.A. | Trpm8 antagonists |
-
2012
- 2012-12-19 SI SI201231328T patent/SI2793883T1/en unknown
- 2012-12-19 HU HUE12812229A patent/HUE038407T2/en unknown
- 2012-12-19 EP EP12812229.8A patent/EP2793883B1/en active Active
- 2012-12-19 KR KR1020147019697A patent/KR102000319B1/en active IP Right Grant
- 2012-12-19 LT LTEP12812229.8T patent/LT2793883T/en unknown
- 2012-12-19 WO PCT/EP2012/076147 patent/WO2013092711A1/en active Application Filing
- 2012-12-19 DK DK12812229.8T patent/DK2793883T3/en active
- 2012-12-19 RS RS20180793A patent/RS57389B1/en unknown
- 2012-12-19 AU AU2012357747A patent/AU2012357747B2/en active Active
- 2012-12-19 PT PT128122298T patent/PT2793883T/en unknown
- 2012-12-19 PL PL12812229T patent/PL2793883T3/en unknown
- 2012-12-19 ME MEP-2018-177A patent/ME03038B/en unknown
- 2012-12-19 JP JP2014547975A patent/JP6238906B2/en active Active
- 2012-12-19 EA EA201491213A patent/EA025356B1/en unknown
- 2012-12-19 ES ES12812229.8T patent/ES2676884T3/en active Active
- 2012-12-19 CN CN201280069993.7A patent/CN104220069B/en active Active
- 2012-12-19 US US14/366,796 patent/US9585875B2/en active Active
- 2012-12-19 TR TR2018/08861T patent/TR201808861T4/en unknown
-
2014
- 2014-06-19 ZA ZA2014/04499A patent/ZA201404499B/en unknown
-
2015
- 2015-03-25 HK HK15103054.0A patent/HK1203810A1/en unknown
-
2017
- 2017-01-25 US US15/414,803 patent/US9856246B2/en active Active
- 2017-06-19 JP JP2017119493A patent/JP2017197564A/en not_active Withdrawn
-
2018
- 2018-07-10 CY CY20181100717T patent/CY1120403T1/en unknown
- 2018-07-11 HR HRP20181086TT patent/HRP20181086T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
SI2793883T1 (en) | 2018-08-31 |
PT2793883T (en) | 2018-07-18 |
US9585875B2 (en) | 2017-03-07 |
WO2013092711A1 (en) | 2013-06-27 |
DK2793883T3 (en) | 2018-07-30 |
ZA201404499B (en) | 2015-12-23 |
ES2676884T3 (en) | 2018-07-25 |
HUE038407T2 (en) | 2018-10-29 |
AU2012357747B2 (en) | 2017-09-07 |
CN104220069B (en) | 2018-10-02 |
ME03038B (en) | 2018-10-20 |
LT2793883T (en) | 2018-08-10 |
RS57389B1 (en) | 2018-09-28 |
AU2012357747A2 (en) | 2014-08-21 |
JP2015504874A (en) | 2015-02-16 |
EP2793883A1 (en) | 2014-10-29 |
EP2793883B1 (en) | 2018-04-18 |
US20170129881A1 (en) | 2017-05-11 |
TR201808861T4 (en) | 2018-07-23 |
US9856246B2 (en) | 2018-01-02 |
JP2017197564A (en) | 2017-11-02 |
AU2012357747A1 (en) | 2014-07-10 |
KR20150000870A (en) | 2015-01-05 |
HRP20181086T1 (en) | 2018-09-07 |
CY1120403T1 (en) | 2019-07-10 |
AU2012357747A8 (en) | 2014-07-24 |
EA025356B1 (en) | 2016-12-30 |
PL2793883T3 (en) | 2018-09-28 |
HK1203810A1 (en) | 2015-11-06 |
KR102000319B1 (en) | 2019-09-27 |
JP6238906B2 (en) | 2017-11-29 |
CN104220069A (en) | 2014-12-17 |
US20140371276A1 (en) | 2014-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201491213A1 (en) | ANTAGONISTS TRPM8 | |
PH12015501116A1 (en) | New indanyloxydihydrobenzofuranylacetic acids | |
PH12014502141A1 (en) | New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists | |
CL2013001295A1 (en) | Compounds derived from 2,3-dihydromidazo (1,2-c) quinazoline substituted with amino alcohols; intermediate compound and its use; pharmaceutical composition; pharmaceutical combination; and its use to treat hyperproliferative disorders and diseases associated with angiogenesis. | |
CR20130308A (en) | COMPOUNDS AND ITS USE AS BACE INHIBITORS | |
CR20120097A (en) | NEW ANTIGONISTS OF PYRIMIDINHEPCIDINE AND TRIAZINHEPCIDINE | |
EA200970835A1 (en) | INDAZOLS APPLICABLE FOR THE TREATMENT OF DISORDERS MEDIATED BY ESTROGEN BETA RECEPTOR | |
EA020330B3 (en) | Quinazoline compounds | |
EA201001647A1 (en) | DERIVATIVES OF BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOLE AS A FXR MODULATORS | |
EA201400161A1 (en) | SUBSTITUTED HETEROAROMATIC PYRAZOL-CONTAINING CARBOXAMIDE AND UTERIN DERIVATIVES AS VIANILLOID RECEPTOR LIGANDS | |
BR112015015468B8 (en) | COMPOUND AND PHARMACEUTICAL COMPOSITION | |
EA201100138A1 (en) | 4-PHENOXYMETHYL-PIPERIDINES AS MODEL ACTIVITY GPR119 | |
EA201200473A1 (en) | SUBSTITUTED (HETEROARILMETHYL) THIOGIDANTOINES | |
CL2015002202A1 (en) | Benzamides substituted with activity towards ep4 receptors. | |
EA201590562A1 (en) | БЕНЗАМИДЫ | |
EA201490152A1 (en) | TRPM8 ANTAGONISTS AND THEIR APPLICATION IN TREATMENT | |
BR112014001908A2 (en) | substituted heterocyclic aza derivatives | |
EA201100921A1 (en) | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR APPLICATION IN THE TREATMENT OF MATERIAL EXCHANGE DISORDERS | |
MX349254B (en) | Compounds for treatment of metabolic syndrome. | |
MX2011012669A (en) | Novel glucocorticoid receptor agonists. | |
PH12016500092B1 (en) | New azabenzimidazole derivatives | |
ATE481972T1 (en) | QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | |
EA201001842A1 (en) | NEW CONNECTIONS WITH THE ACTIVITY OF ANTAGONISTS OF MUSCARINE RECEPTORS | |
EA201790072A1 (en) | DERIVATIVES 2-ARYL-4-HYDROXY-1,3-TIAZOLE FOR USE AS TRPM8 INHIBITORS IN THE TREATMENT OF NEURALGIA, PAIN, CHRONIC OBSTRUCTIVE LUNG AND ASTHMA | |
BR112014001714A2 (en) | substituted bicyclic aromatic carboxamide and urea derivatives as vanyloid receptor ligands |